Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388527 | 0.91 | CYP2D6 (0.74) | CYP2D6CYP1A2HTR2AHTR2CSCN1A | |
| SCHEMBL420300 | 0.91 | CYP2D6 (0.74) | CYP2D6CYP1A2HTR2AHTR2CSCN1A | |
| SCHEMBL10376015 | 0.86 | CYP2D6 (0.67) | CYP2D6CYP1A2KMT2AACHEALDH1A1 | |
| SCHEMBL657896 | 0.86 | CYP2D6 (0.67) | CYP2D6CYP1A2KMT2AACHEALDH1A1 | |
| SCHEMBL8879797 | 0.84 | CYP2D6 (0.66) | CYP2D6CYP1A2KMT2APKMALDH1A1 | |
| SCHEMBL28419751 | 0.84 | CYP2D6 (0.66) | CYP2D6CYP1A2KMT2APKMALDH1A1 | |
| SCHEMBL28966911 | 0.83 | CYP2D6 (0.64) | CYP2D6CYP1A2HTR2AHTR2CKMT2A | |
| SCHEMBL6121238 | 0.83 | CYP2D6 (0.64) | CYP2D6CYP1A2HTR2AHTR2CKMT2A | |
| SCHEMBL6198035 | 0.83 | CYP2D6 (0.63) | CYP2D6CYP1A2KMT2APKMACHE | |
| SCHEMBL777214 | 0.83 | CYP2D6 (0.63) | CYP2D6CYP1A2KMT2APKMACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630530-B2 | FGFR inhibitor compound and use thereof | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-4635956-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-20250101001-A1 | CONSTRAINED AMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4186894-B1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024125631-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-118206559-A | PROTAC chimeric compounds, preparation method and use thereof | 杭州中美华东制药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-113795256-B | FGFR inhibitors for treatment of cancer | 布里奇恩生物科学公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS | 2021-08-17 | — | — | US | disclosed |
| WO-2020168237-A1 | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRIDGENE BIOSCIENCES, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3385262-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | Gan & Lee Pharmaceuticals (CN) | 2018-10-10 | — | — | EP | disclosed |
| US-20170183342-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC | 2017-06-29 | — | — | US | disclosed |
| WO-2017092635-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | 甘李药业股份有限公司 | 2017-06-08 | — | — | WO | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| US-5086051-A | 1H, 3H-pyrrolo[1,2-c]thiazole-7-carboxamide derivatives and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183342-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM5, CHRM4, CHRM1 | CYP2D6 361/4885CYP1A2 935/4885HTR2A 210/4885 |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CYP2D6 1735/4885CYP1A2 2808/4885HTR2A 3327/4885 |
| US-12630530-B2 | FGFR inhibitor compound and use thereof | FGFR3, FGFR1, FGFR4 | CYP2D6 351/4885CYP1A2 1089/4885HTR2A 3969/4885 |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | CYP2D6 1735/4885CYP1A2 2808/4885HTR2A 3327/4885 |
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CXCR1, TXK, CXCR4 | CYP2D6 1464/4885CYP1A2 3587/4885HTR2A 3120/4885 |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | CYP2D6 1735/4885CYP1A2 2808/4885HTR2A 3327/4885 |
| US-20250101001-A1 | CONSTRAINED AMINE PSYCHOPLASTOGENS AND USES THEREOF | CHAT, SLC18A2, PNMT | CYP2D6 4654/4885CYP1A2 3300/4885HTR2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.